Apogenix AG: Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology

Written by Petra Hegmann on 19th September 2019. Posted in Client News.

• Previous
• Next